A new study led by Carla Finkielstein, an associate professor at the Fralin Biomedical Research Institute at VTC, and Diego Golombek, a professor at the National University of Quilmes, reveals that chronic jet lag impedes the body’s immune system and also changes the tumor microenvironment, favoring tumor growth.
Roanoke-based cancer research startup, Acomhal Research Inc., secured a $399,878 Small Business Technology Transfer grant to determine if a molecule that stalls the spread of invasive brain cancer stem cells can help treat aggressive forms of breast cancer.
Finkielstein, a molecular biologist and an associate professor in the College of Science, will join the Fralin Biomedical Research Institute at VTC on July 1. Her laboratory, which studies how circadian rhythms are involved in breast cancer progression, will move to the Health Sciences and Technology Campus in Roanoke.
The campus is an expansion of Children’s National that is located on a nearly 12-acre portion of the former Walter Reed Army Medical Center in Washington, D.C., and is set to open its first phase in December 2020.
Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body’s sleep cycle is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.
Deb Kelly, who is also an associate professor of biological sciences in the College of Science at Virginia Tech, is working to better detect, prevent, and repair the mutations found in cancers related to the breast cancer susceptibility protein, BRCA1.
The program is based on the Virginia Tech Carilion Health Sciences and Technology Campus in Roanoke, and it positions students to conduct research in more than 50 departments and institutes across Virginia Tech.
Students and alumni nominated individuals who provided clear expectations and high standards for students to conduct original hypothesis-driven research effectively and provide opportunities for professional growth.
The National Cancer Institute of the National Institutes of Health has awarded Deborah Kelly, an associate professor at the Virginia Tech Carilion Research Institute, $2 million to study the mutated form of the breast cancer susceptibility protein that is implicated in hereditary breast cancer.
Von Hippel-Lindau syndrome is a rare disease, affecting about one in every 36,000 people, according to the National Institutes of Health. People with the disorder have an increased risk for developing cancer, but a main concern is on the syndrome’s characteristic benign growths.
Acomhal Research Inc., formed to fight a deadly type of brain cancer, is being recognized this week by the Association of Public and Land-Grant Universities and the Association of American Universities.
Their results, published this week in Science Advances, suggest a new paradigm for better managing the mutated BRCA1 protein found in triple-negative breast cancer cells. Triple-negative breast cancer is aggressive, as its tumor cells typically lack target receptors that allow cancer-fighting drugs to be effective.
Research teams at the Virginia Tech Carilion Research Institute from three colleges — Engineering, Science, and Veterinary Medicine — are developing new approaches to treat glioblastoma, the aggressive form of brain cancer recently diagnosed in U.S. Sen. John McCain.
At the Virginia Tech Carilion Research Institute, three scientists are planning to create a virus capable of destroying brain cancer. It sounds like the stuff of science fiction, but it isn’t hypothetical – the researchers were recently awarded a grant from the Commonwealth Research Commercialization Fund, part of the Center for Innovative Technology, to engineer a viral therapy.